Spark Therapeutics Gains Panel Nod For Gene Therapy To Treat Blindness

A gene therapy from Spark Therapeutics (ONCE) to treat a rare eye disease should gain full Food and Drug Administration approval, reports said Thursday.

XAutoplay: On | OffThe FDA's Cellular, Tissue and Gene Therapies Advisory Committee voted unanimously to recommend the full FDA approve a treatment called Luxturna to treat patient with vision loss due to an inherited retinal disease, according to Reuters.

Representatives of the committee and Spark didn't immediately return requests from...

What feeling does this article give you?

#hashtags to follow:

Spark Therapeutics [+]    Food and Drug Administration [+]    XAutoplay [+]    FDA [+]    Cellular [+]    Luxturna [+]    Reuters [+]    Representatives [+]   

More #news: